A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ROS1-rearranged Non-squamous Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ROS1 under Crizotinib treatment and the consistency of plasma and tissue detection driving genes, and finally evaluate the mutation spectrum of plasma dynamic detection driving genes. In predicting the risk of disease progression.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• ROS1 Arranged Positive
• ROS1 Arranged Detection Method is NGS
• First Diagnosis and Treatment
• Treatment Plan is Kazolinib 250mg po bid
Locations
Other Locations
China
Hunan Cancer Hospital
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Nong Yang, MD
yangnong0217@163.com
+8613873123436
Time Frame
Start Date: 2018-08-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 40
Treatments
Cohorts 1
ROS1 fusion positive NSCLC patients who received crizotinib
Authors
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital